Lovastatin increases surface low density lipoprotein receptor expression by retarding the receptor internalization...

Area of Science:

• Immunology
• Pharmacology
• Cell Biology

Background:

• Lymphocytes play a role in immune responses.
• Low-density lipoprotein receptors (LDL-R) are crucial for cholesterol homeostasis.
• Lovastatin is a statin drug used to lower cholesterol.

Purpose of the Study:

• To investigate the effects of Lovastatin on LDL receptor expression and internalization in lymphocytes.
• To determine if Lovastatin's effects are related to its impact on cell proliferation or the mevalonate pathway.

Main Methods:

• Lymphocytes were stimulated with phytohemagglutinin and expanded with interleukin-2.
• Cells were treated with varying concentrations of Lovastatin.
• LDL receptor expression and DiI-LDL uptake were measured.
• LDL receptor internalization rate was assessed using monensin.
• Effects of hydroxyurea and genistein on internalization were examined.
• Restoration of internalization was tested using mevalonate or LDL.

Main Results:

• Lovastatin increased surface LDL receptor expression by up to 30% without affecting DiI-LDL uptake.
• A dose-dependent reduction in LDL receptor internalization rate was observed with Lovastatin.
• Lovastatin did not affect IL-2 receptor internalization.
• Inhibition of DNA synthesis or protein tyrosine kinase activity did not alter LDL receptor internalization.
• Mevalonate or LDL co-incubation restored the LDL receptor internalization rate.

Conclusions:

• Lovastatin increases apparent surface LDL receptor expression by reducing the rate of LDL receptor internalization.
• The observed effect is mediated by the mevalonate pathway.
• Lovastatin's anti-mitogenic properties do not contribute to this effect on LDL receptors.